|
Assessment of the effectiveness of neoadjuvant chemotherapy for rectal cancer by MRI and PETCT: a meta-analysis
|
P. Zhao   , Y. Xu , C. Xie , M. Zhan , Y. Qian , Z. Gao |
| Department of Radiology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hanghzou, Zhejiang, 311200, China , XcmandTT@163.com |
|
|
Abstract: (295 Views) |
Background: A meta-analysis of the effectiveness of Magnetic Resonance Imaging (MRI) and Positron Emission Tomography Computed Tomography (PETCT) in assessing the effects of neoadjuvant chemotherapy (nCRT) for Rectal cancer (RC) was performed to provide a reference for better clinical assessment in the future. Materials and Methods: Relevant literature on the assessment of the effects of MRI and PETCT on RC nCRT was screened through PubMed, Cochrane, EMBAS and other literature databases, and the final literature for analysis was determined after cross-screening by two study team members. Review Manager 5.3 software was used to assess the quality of the literature and extract relevant information such as authors, year of publication, and results, and meta-analysis was performed using Stata 15.1 software. Results: Through screening, six references were finally included, totaling 396 cases of study subjects, and the results of literature quality evaluation showed that the selected literature was of high quality and had some reference value. Meta-analysis revealed a sensitivity of 0.76 and a specificity of 0.74 for the final combination of MRI; the sensitivity and specificity of the final combined PETCT were 0.78 and 0.71, respectively. Deek’s test showed P>0.05 for both MRI and PETCT, with no publication bias. Conclusion: MRI and PETCT are similarly effective in predicting the effect of RC nCRT. |
|
| Keywords: Magnetic resonance imaging, positron emission tomography computed tomography, rectal neoplasms, meta-analysis, neoadjuvant therapy. |
|
|
Full-Text [PDF 917 kb]
(125 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. Bray F, Ferlay J, Soerjomataram I, et al. (2020) Global cancer statistics 2018: GLOBORCN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. RC Cancer J Clin, 68(6): 394-424. [ DOI:10.3322/caac.21492] 2. van Gijn W, Marijnen CA, Nagtegaal ID, et al. (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol, 12: 575-82. [ DOI:10.1016/S1470-2045(11)70097-3] 3. Locally advanced rectal cancer: the past, present, and future. Semin Oncol (2020) Locally advanced rectal cancer: the past, present, and future. Semin Oncol, 47: 85-92. [ DOI:10.1053/j.seminoncol.2020.02.001] 4. Maas M, Nelemans PJ, Valentini V, et al. (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol, 11(9): 835-44. [ DOI:10.1016/S1470-2045(10)70172-8] 5. Polanco PM, Mokdad AA, Zhu H, et al. (2018) Association of Adjuvant Chemotherapy With Overall Survival in Patients With Rectal Cancer and Pathologic Complete Response Following Neoadjuvant Chemotherapy and Resection. JAMA Oncolm, 4(7): 938-943. [ DOI:10.1001/jamaoncol.2018.0231] 6. Fokas E, Schlenska-Lange A, Polat B, et al. German Rectal Cancer Study Group (2022) Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol, 8(1): e215445. [ DOI:10.1001/jamaoncol.2021.5445] 7. Martin ST, Heneghan HM, Winter DC (2012) Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg, 99(7): 918-28. [ DOI:10.1002/bjs.8702] 8. Smith JJ, Strombom P, Chow OS, et al. (2019) Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after Neoadjuvant therapy. JAMA Oncol, 5(4): e185896. [ DOI:10.1001/jamaoncol.2018.5896] 9. Dossa F, Chesney TR, Acuna SA, Baxter NN (2017) A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2(7): 501-513. [ DOI:10.1016/S2468-1253(17)30074-2] 10. van der Valk MJM, Hilling DE, Bastiaannet E, et al. IWWD Consortium (2018) Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet, 391(10139): 2537-2545. [ DOI:10.1016/S0140-6736(18)31078-X] 11. Gollub MJ, Tong T, Weiser M, et al. (2017) Limited accuracy of DCE-MRI in identification of pathological complete responders after chemoradiotherapy treatment for rectal cancer. Eur Radiol, 27(4): 1605-1612. [ DOI:10.1007/s00330-016-4493-1] 12. Beets-Tan RGH, Lambregts DMJ, Maas M, et al. (2018) Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol, 28(4): 1465-1475. [ DOI:10.1007/s00330-017-5026-2] 13. Kalisz KR, Enzerra MD, Paspulati RM (2019) MRI evaluation of the response of rectal cancer to neoadjuvant chemoradiation therapy. Radiographics, 39(2): 538-556. [ DOI:10.1148/rg.2019180075] 14. Uemura M, Ikeda M, Handa R, et al. (2021) The efficiency of 18F-FDG-PET/CT in the assessment of tumor response to preoperative chemoradiation therapy for locally recurrent rectal cancer. BMC Cancer, 21(1): 1132. [ DOI:10.1186/s12885-021-08873-7] 15. López-López V, Abrisqueta Carrión J, et al. (2021) Assessing tumor response to neoadjuvant chemoradiation in rectal cancer with rectoscopy and 18F-FDG PET/CT: results from a prospective series. Rev Esp Enferm Dig, 113(5): 307-312. [ DOI:10.17235/reed.2020.6954/2020] 16. Chen SH, Miles K, Taylor SA, et al. (2021) FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis. Eur J Nucl Med Mol Imaging, 49(1): 371-384. [ DOI:10.1007/s00259-021-05318-y] 17. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2 Group (2011) QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med, 155(8): 529-36. [ DOI:10.7326/0003-4819-155-8-201110180-00009] 18. Giannini V, Mazzetti S, Bertotto I, et al. (2019) Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features. Eur J Nucl Med Mol Imaging, 46(4): 878-888. [ DOI:10.1007/s00259-018-4250-6] 19. Aiba T, Uehara K, Nihashi T, et al. (2014) MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer. Ann Surg Oncol, 21(6): 1801-8. [ DOI:10.1245/s10434-014-3538-4] 20. Huh JW, Kwon SY, Lee JH, Kim HR (2015) Comparison of restaging accuracy of repeat FDG-PET/CT with pelvic MRI after preoperative chemoradiation in patients with rectal cancer. J Cancer Res Clin Oncol, 141(2): 353-9. [ DOI:10.1007/s00432-014-1815-z] 21. Herrmann K, Bundschuh RA, Rosenberg R, et al. (2011) Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI. Mol Imaging Biol, 13(5): 1011-9. [ DOI:10.1007/s11307-010-0383-0] 22. Uslu-Beşli L, Mermut Ö, Yardimci AH, et al. (2021) Comparison of 18F-FDG PET/CT and DW-MRI in assessment of neoadjuvant radiochemotherapy response in locally advanced rectal cancer patients. Rev Esp Med Nucl Imagen Mol (Engl Ed), 40(1): 19-29. [ DOI:10.1016/j.remnie.2020.03.007] 23. Petrillo A, Fusco R, Petrillo M, et al. (2017) Standardized index of shape (DCE-MRI) and standardized uptake value (PET/CT): Two quantitative approaches to discriminate chemo-radiotherapy locally advanced rectal cancer responders under a functional profile. Oncotarget, 8(5): 8143-8153. [ DOI:10.18632/oncotarget.14106] 24. Habr-Gama A, São Julião GP, Vailati BB, et al. (2019) Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: The impact of radiation therapy dose-escalation and consolidation chemotherapy. Ann Surg, 269(1): 102-107. [ DOI:10.1097/SLA.0000000000002447] 25. Wen L, Liu J, Hu P, et al. (2023) MRI-based radiomic models outperform radiologists in predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Acad Radiol, S1076-6332(22)00692-4. [ DOI:10.1016/j.acra.2022.12.037] 26. Xiang Y, Li S, Wang H, et al. (2022) MRI-based radiomics to predict neoadjuvant chemoradiotherapy outcomes in locally advanced rectal cancer: A multicenter study. Clin Transl Radiat Oncol, 38: 175-182. [ DOI:10.1016/j.ctro.2022.11.009] 27. Gülbahar Ateş S, Bilir Dilek G, Uçmak G (2023) Primary tumor heterogeneity on pretreatment 18F-FDG PET/CT to predict outcome in patients with rectal cancer who underwent surgery after neoadjuvant therapy. Rev Esp Med Nucl Imagen Mol (Engl Ed), S2253-8089(23)00001-0. [ DOI:10.1016/j.remnie.2023.01.001] 28. Liu Y, Zheng D, Liu JJ, et al. (2019) Comparing PET/MRI with PET/CT for Pretreatment Staging of Gastric Cancer. Gastroenterol Res Pract, 2019: 9564627. [ DOI:10.1155/2019/9564627] 29. Eshaghi M (2020) The effect of pain management on pain reduction in women with breast cancer. SJMSHM, 2(2): 1-5. [ DOI:10.29252/sjmshm.2.2.1] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Zhao P, Xu Y, Xie C, Zhan M, Qian Y, Gao Z. Assessment of the effectiveness of neoadjuvant chemotherapy for rectal cancer by MRI and PETCT: a meta-analysis. Int J Radiat Res 2024; 22 (1) :85-90 URL: http://ijrr.com/article-1-5217-en.html
|
